Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

200.59 -4.62 (-2.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
 
Via Benzinga
How Is The Market Feeling About Ascendis Pharma?
 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
 
Via Benzinga
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
Ascendis Pharma's Earnings: A Preview
 
Via Benzinga
$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
Ascendis Pharma A/S (NASDAQ: ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth... 
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
 
Via Benzinga
Recap: Ascendis Pharma Q3 Earnings
 
Via Benzinga
Preview: Ascendis Pharma's Earnings
 
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
 
Via Benzinga
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in  
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
 
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Earnings Scheduled For September 5, 2023
Companies Reporting Before The Bell • Procaps Gr (NASDAQ:PROC) is likely to report earnings for its second quarter. 
Via Benzinga
Earnings Preview For Ascendis Pharma
 
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
 
Via Benzinga
Where Ascendis Pharma Stands With Analysts
 
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
 
Via Benzinga
FDA Rejects Ascendis Pharma's TransCon PTH For Hypoparathyroidism
The FDA issued a complete response letter (CRL) for Ascendis Pharma A/S's 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors. 
Via SBWire
Why Shares of Ascendis Pharma Are Climbing Monday
A critical response letter from the FDA means hope remains for the company's hyperthyroidism therapy candidate. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up... 
Via Benzinga
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market trading... 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why.
So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.